AbbVie price target raised to $240 from $200 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $240 from $200 and keeps an Overweight rating on the shares. The firm raised its sales estimates for Skyrizi and Rinvoq since their uptake has been more robust than it had previously anticipated, the analyst tells investors in a research note.